3种治疗下呼吸道感染方案的成本—效果分析

摘要

OBJECTIVE:To evaluate the pharmacoeconomic effectiveness of three therapeutic schemes for lower respiratory tract infections.METHODS:The cost-effectiveness analysis of three therapeutic schemes for lower respiratory tract infections was carried out.RESULTS:The cost-effectiveness ratio of penicillin-piperacillin schemes(L1)was minimum in respect to the effective rate.However,the cost-effectiveness ratios had no significant difference between cefotaxime scheme(L3)and L1 scheme in regard to cure rate(P>0.05),the cost-effectiveness ratio of ciprofloxacin-clinadmacin scheme(L2) was higher significantly than those of L1 and L3 schemes(P<0.05,both schemes).CONCLUSION： L1 is the best therapeutic scheme.Although L3 scheme had higher cost,it had higher cure rate and lower ADRs occurrence.L3 scheme is benefitial to improvement of patient's life quality.%目的:评价下呼吸道感染的3种治疗方案所产生的药物经济学效果。方法:运用成本—效果分析法对3种治疗方案进行分析。结果:从有效率来看，青霉素—哌拉西林组(L1组)的成本—效果比最小；从治愈率来看，头孢噻肟钠组(L3)与L1组的成本—效果比无显著性差异(P>0.05)，而环丙沙星—克林霉素组(L2)的成本—效果比明显高于L1组和L3组(P<0.05）。结论：L1组为最佳治疗方案，L3组虽然成本高，但治愈率也高，不良反应少，有利于提高患者生命质量。